Comprehensive genomic profiling of matched glioblastoma tumours, cell-lines, and xenografts reveals genomic stability and adaptation to disparate growth environments
The mandate of this project was to use drug screening to deliver new drugs for glioblastoma (GBM) to clinical trials, and perform genomic assessment of GBM to discover new therapeutic targets and predictors of response. The sequencing data in this set was derived from GBM patient tumor samples, matched brain tumor initiating cells lines (BTICs), and tumor tissue derived from orthotopic implants.
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001004221 | Illumina HiSeq 2000 | - | |
EGAD00001004222 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 2 | |
EGAD00001004223 | Illumina HiSeq 2000 | - | |
EGAD00001004224 | Illumina HiSeq 2500 | - | |
EGAD00001004225 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 2 | |
EGAD00001004226 | Illumina HiSeq 2500 | - | |
EGAD00001004227 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 1 | |
EGAD00001004228 | Illumina HiSeq 2500 | - | |
EGAD00001004229 | Illumina HiSeq 2000 | 1 | |
EGAD00001004230 | Illumina HiSeq 2000 Illumina HiSeq 2500 | - | |
EGAD00001004231 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 2 | |
EGAD00001004232 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 2 | |
EGAD00001004233 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 1 | |
EGAD00001004234 | Illumina HiSeq 2000 Illumina HiSeq 2500 | - | |
EGAD00001004235 | Illumina HiSeq 2000 | 1 | |
EGAD00001004236 | - | ||
EGAD00001004237 | Illumina HiSeq 2000 | - | |
EGAD00001004238 | Illumina HiSeq 2500 | - | |
EGAD00001004239 | Illumina HiSeq 2500 | 1 | |
EGAD00001004240 | Illumina HiSeq 2500 | 2 | |
EGAD00001004241 | Illumina HiSeq 2500 | - | |
EGAD00001004242 | Illumina HiSeq 2500 | - | |
EGAD00001004243 | Illumina HiSeq 2000 Illumina HiSeq 2500 | - | |
EGAD00001004244 | - | ||
EGAD00001004245 | Illumina HiSeq 2000 | - | |
EGAD00001004246 | Illumina HiSeq 2000 Illumina HiSeq 2500 | - | |
EGAD00001004247 | Illumina HiSeq 2500 | - | |
EGAD00001004248 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 1 | |
EGAD00001004249 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 1 | |
EGAD00001004250 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 1 | |
EGAD00001004251 | Illumina HiSeq 2000 | - | |
EGAD00001004252 | Illumina HiSeq 2000 | - | |
EGAD00001004253 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 3 | |
EGAD00001004254 | Illumina HiSeq 2500 | 1 | |
EGAD00001004255 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 1 | |
EGAD00001004256 | Illumina HiSeq 2000 Illumina HiSeq 2500 | - | |
EGAD00001004257 | Illumina HiSeq 2000 | 1 | |
EGAD00001004258 | Illumina HiSeq 2000 | - | |
EGAD00001004259 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 1 | |
EGAD00001004260 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 1 | |
EGAD00001004261 | Illumina HiSeq 2000 | 1 | |
EGAD00001004262 | Illumina HiSeq 2500 | 1 | |
EGAD00001004263 | Illumina HiSeq 2000 Illumina HiSeq 2500 | - | |
EGAD00001004264 | Illumina HiSeq 2500 | 1 | |
EGAD00001008516 | Illumina HiSeq 2500 | 1 | |
EGAD00001008517 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 2 | |
EGAD00001008518 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 2 | |
EGAD00001008519 | Illumina HiSeq 2000 | 1 | |
EGAD00001008520 | Illumina HiSeq 2000 | 1 | |
EGAD00001008521 | Illumina HiSeq 2000 | 1 | |
EGAD00001008522 | Illumina HiSeq 2500 | 1 | |
EGAD00001008523 | Illumina HiSeq 2500 | 1 | |
EGAD00001008524 | - | ||
EGAD00001008525 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 2 | |
EGAD00001008526 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 5 | |
EGAD00001008527 | Illumina HiSeq 2500 | 1 | |
EGAD00001008528 | - | ||
EGAD00001008529 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 3 | |
EGAD00001008530 | Illumina HiSeq 2000 Illumina HiSeq 2500 | 3 | |
EGAD00001008531 | Illumina HiSeq 2500 | 1 | |
EGAD00001008532 | Illumina HiSeq 2000 | 1 |
Publications | Citations |
---|---|
Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.
Proc Natl Acad Sci U S A 116: 2019 19098-19108 |
26 |
SLUG Directs the Precursor State of Human Brain Tumor Stem Cells.
Cancers (Basel) 11: 2019 E1635 |
8 |
Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression.
Nat Commun 11: 2020 4997 |
84 |
Spatiotemporal modeling reveals high-resolution invasion states in glioblastoma.
Genome Biol 25: 2024 264 |
0 |